CPDR Patient Education Program
Industry-Sponsored Clinical Trials and Projects
The CRC maintains a comprehensive portfolio of both investigator-initiated and industry sponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, are investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. All trials and projects are carried out with full approval of the respective IRBs.
CPDR Open Clinical Trials
ProstAtak TrialA randomized trial of ProstAtak in combination with standard external beam radiation therapy with or without androgen deprivation therapy is in men with intermediate to high risk localized prostate cancer. ProstAtak is an investigational product that is meant to kill tumor cells and elicit an anti-tumor vaccine effect. In a Phase II clinical trial of ProstAtak given with radiation, prostate cancer recurrence was three-fold lower than typically seen with radiation alone. The purpose of this Phase III trial is to definitively determine if ProstAtak reduces prostate cancer recurrence
BAYER - RADIUM 223A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride (radium 223 dichloride is FDA approved drug that targets prostate cancer in the bones), in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer
AMOR3-SVA phase 3, randomized, open-label, multi-center, controlled study of Galeterone compared to Enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) with metastatic (M1) castrate resistant prostate cancer (CRPC). Galeterone is a selective, multi-targeted, small molecule drug for the treatment of castrate resistant prostate cancer
CONTACT Information: Judith A. Travis, RN, Walter Reed National Military Medical Center, Center for Prostate Disease Research, America Building 19, Room 3225 on the 3rd floor.
301-319-2927 or Judith.email@example.com
June 23, 2016
Dr. Charles P. Xavier Takes the Robert A. Phillips Award and a Navy-wide Academic Research Competition Award
by Paula Amann
Published in the June 2016 issue of Military Medical Research News, a monthly newsletter of the Department of Research Programs, Walter Reed National Military Medical Center.
Fine-tuning facial transplants, predicting bone fractures, shrinking prostate cancers with new drugs and cutting the costs of surgical training with the right technology: These were among the problems probed by competition winners for 2016 Research and Innovation Month at Walter Reed National Military Medical Center (WRNMMC).
The events, during Poster Display Week on May 11 and the Research Symposia on May 18-19, drew abstracts for 178 projects. After winnowing by pre-selection judges, 22 finalists emerged in three categories: case reports, evidence-based practice and quality improvement (a crucial non-research area).
Another 24 finalists, split evenly between laboratory and clinical research, vied for the Robert A. Phillips (RAP) and Bailey K. Ashford (BKA) Awards. The two BKA winners were LCDR Gabriel Santiago, MC (laboratory medicine), and LT Scott Wagner, MC (clinical medicine).
RAP winners included LT Daniel Griffin, MC (resident laboratory category); CPT Sarah Placek, MC (resident clinical); Charles P. Xavier, Ph.D. (staff laboratory); and Benjamin Sheffield (staff clinical).
or go to theWRNMMC UsToo! Newsletter Archive
Read the AUGUST 2016 CPDR E-Newsletter